Skip to content

Study · Not a test of the peptide alone · 2007

2 results

A 30-kDa fragment of insulin-like growth factor (IGF) binding protein-3 in human pregnancy serum with strongly reduced IGF-I binding.

Ahlsén M, Carlsson-Skwirut C, Jonsson AP, Cederlund E, Bergman T, Bang P

Cellular and molecular life sciences : CMLS1 Jul 2007Cited by 10 (Europe PMC)

PMID17593323 (opens in a new tab)PMCIDPMC11136294 (opens in a new tab)DOI10.1007/s00018-007-7201-0 (opens in a new tab)PepBankPUB-17593323
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Mechanism

    In biosensor tests, des(1‑3)IGF-I results suggested fast IGF-I binding to the N-terminal region of IGFBP-3.

    In plain wordsIn lab tests, des(1‑3)IGF-I results suggested that IGF-I binds quickly to the front region of IGFBP-3.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableN-terminal IGFBP-3 binding kinetics
    Study

    n: not reported in source

    IGFBP-3 biosensor binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Tests with des(1-3)IGF-I suggest fast binding of IGF-I to the N-terminal region of IGFBP-3 and similar affinity to a slow binding site in the C-terminal region.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Mechanism

    In biosensor tests, des(1‑3)IGF-I results suggested similar affinity for a slow binding site in the C-terminal region of IGFBP-3.

    In plain wordsIn lab tests, des(1‑3)IGF-I results suggested similar binding strength at a slow binding site in the rear region of IGFBP-3.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeC-terminal IGFBP-3 binding affinity
    Study

    n: not reported in source

    IGFBP-3 biosensor binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Tests with des(1-3)IGF-I suggest fast binding of IGF-I to the N-terminal region of IGFBP-3 and similar affinity to a slow binding site in the C-terminal region.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.